RET and non-small cell lung carcinoma: In September 2020, the FDA granted accelerated approval for pralsetinib to treat adult patients with metastatic fusion RET positive NSCLC, and on December 2020, for advanced or metastatic medullary thyroid cancer with genetically defective RET [217].